Purpose of this non-interventional study is the documentation of efficacy and safety data of multiple myeloma therapy with a combined treatment of Lenalidomide and Dexamethasone in daily routine practice.
Study Type
OBSERVATIONAL
Enrollment
101
Onkologische Schwerpunktpraxis
Bad Homburg, Germany
Onkologische Schwerpunktpraxis
Berlin, Germany
Time to progression (TTP)
Time frame: maximum 3 years per Patient
Overall Response Rate
Time frame: maximum 3 years per Patient
Time to Treatment Discontinuation (TTD)
Time frame: maximum 3 years per Patient
Overall Survival (OS)
Time frame: maximum 3 years per Patient
Safety Profile
Time frame: maximum 3 years per Patient
Dosage of Lenalidomide and Dexamethasone
Time frame: maximum 3 years per Patient
Kidney Function
Time frame: maximum 3 years per Patient
Neutropenia / Infection (Concomitant Medication)
Time frame: maximum 3 years per Patient
Thrombosis Prophylaxis
Time frame: maximum 3 years per Patient
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Onkologisches Versorgungszentrum Friedrichshain
Berlin, Germany
Onkologische Praxis
Berlin, Germany
Onkologische Gemeinschaftspraxis
Frankfurt am Main, Germany
Praxis für Innere Medizin
Germering, Germany
MedResearch - Medizinisches Studien- und Dokumentationszentrum Leipziger Land
Groitzsch, Germany
Internistische Gemeinschaftspraxis
Güstrow, Germany
Praxis für Innere Medizin, Haematologie und Internistische Onkologie
Hamburg, Germany
Tumorpraxis Heidenheim
Heidenheim, Germany
...and 10 more locations